Cargando…

Development of a Novel Assay to Assess the Avidity of Dengue Virus-Specific Antibodies Elicited in Response to a Tetravalent Dengue Vaccine

Antibody affinity maturation is a critical step in development of functional antiviral immunity; however, accurate measurement of affinity maturation of polyclonal serum antibody responses to particulate antigens such as virions is challenging. We describe a novel avidity assay employing biolayer in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuji, Isamu, Dominguez, David, Egan, Michael A, Dean, Hansi J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071338/ https://www.ncbi.nlm.nih.gov/pubmed/33534885 http://dx.doi.org/10.1093/infdis/jiab064

Ejemplares similares

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine
por: Byers, Anthony M., et al.
Publicado: (2015)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America
por: Olivera-Botello, Gustavo, et al.
Publicado: (2016)

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate
por: Patel, Sanjay S, et al.
Publicado: (2022)

Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System
por: Nascimento, Eduardo J M, et al.
Publicado: (2022)

Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study
por: Sirivichayakul, Chukiat, et al.
Publicado: (2020)

Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines
por: Swanstrom, Jesica A, et al.
Publicado: (2019)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

A tetravalent nanoparticle vaccine elicits a balanced and potent immune response against dengue viruses without inducing antibody-dependent enhancement
por: Chen, Qier, et al.
Publicado: (2023)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
por: Ambuel, Yuping, et al.
Publicado: (2014)

Correlation between Dengue-Specific Neutralizing Antibodies and Serum Avidity in Primary and Secondary Dengue Virus 3 Natural Infections in Humans
por: Puschnik, Andreas, et al.
Publicado: (2013)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques
por: Fernandez, Stefan, et al.
Publicado: (2015)

Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines
por: Prompetchara, Eakachai, et al.
Publicado: (2014)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties
por: Liu, Yan, et al.
Publicado: (2014)

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses
por: Nemirov, Kirill, et al.
Publicado: (2023)

Erratum: A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
Publicado: (2014)

Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus
por: Nascimento, Eduardo J. M., et al.
Publicado: (2021)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever
por: Subramaniyan, Vijayakumar, et al.
Publicado: (2018)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine
por: El Fezzazi, Hanna, et al.
Publicado: (2017)

Augmented Zika and Dengue Neutralizing Antibodies Are Associated With Guillain-Barré Syndrome
por: Lynch, Rebecca M, et al.
Publicado: (2019)

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype
por: Metz, Stefan W., et al.
Publicado: (2018)

Lectin Switching During Dengue Virus Infection
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2011)

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate
por: Imagawa, Toshifumi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lpcb6ib5ojqpv2djf3shku51d5